MarketWatch.com - Top Stories

Sarepta Therapeutics’ stock falls after patient dies of liver failure

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Mar 18, 2025 - 14:58
 0
Sarepta Therapeutics’ stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More

Tags:

Previous Article

Households plans for long-term care, but those plans may not reflect reality

Next Article

Prediction: These 2 Stocks Will Outperform the Market Through 2030

Related Posts

Stocks saw some pressure because Walmart guidance renewed worries about consumers

Stocks saw some pressure because Walmart guidance renew...

Feb 20, 2025  0

Fed officials worry about inflation sparked by Trump’s tariffs and economic plans

Fed officials worry about inflation sparked by Trump’s ...

Feb 19, 2025  0

National CineMedia is bringing back its dividend, less than two years after bankruptcy. This is why.

National CineMedia is bringing back its dividend, less ...

Mar 13, 2025  0